Understanding high-density lipoprotein function in disease: Recent advances in proteomics unravel the complexity of its composition and biology

Alonzi, 2008, Elucidation of lipoprotein particles structure by proteomic analysis, Expert Rev Proteomics, 5, 91, 10.1586/14789450.5.1.91

Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401

Shepherd, 2002, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial, Lancet, 360, 1623, 10.1016/S0140-6736(02)11600-X

Barter, 2003, High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions, Atherosclerosis, 168, 195, 10.1016/S0021-9150(03)00006-6

Di Angelantonio, 2009, Major lipids, apolipoproteins, and risk of vascular disease, JAMA, 302, 1993, 10.1001/jama.2009.1619

Toth, 2013, High-density lipoproteins: a consensus statement from the National Lipid Association, J Clin Lipidol, 7, 484, 10.1016/j.jacl.2013.08.001

Rosenson, 2013, Translation of high-density lipoprotein function into clinical practice: current prospects and future challenges, Circulation, 128, 1256, 10.1161/CIRCULATIONAHA.113.000962

Shah, 2013, Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond, J Lipid Res, 54, 2575, 10.1194/jlr.R035725

Kontush, 2013, Unraveling the complexities of the HDL lipidome, J Lipid Res, 54, 2950, 10.1194/jlr.R036095

Marsche, 2013, Inflammation alters HDL composition and function: implications for HDL-raising therapies, Pharmacol Ther, 137, 341, 10.1016/j.pharmthera.2012.12.001

Lewis, 2005, New insights into the regulation of HDL metabolism and reverse cholesterol transport, Circ Res, 96, 1221, 10.1161/01.RES.0000170946.56981.5c

Yancey, 2003, Importance of different pathways of cellular cholesterol efflux, Arterioscler Thromb Vasc Biol, 23, 712, 10.1161/01.ATV.0000057572.97137.DD

Kozarsky, 1997, Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels, Nature, 387, 414, 10.1038/387414a0

Moore, 2005, Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation, Circ Res, 97, 763, 10.1161/01.RES.0000185320.82962.F7

Plump, 1994, Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse, Proc Natl Acad Sci USA, 91, 9607, 10.1073/pnas.91.20.9607

Paszty, 1994, Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice, J Clin Invest, 94, 899, 10.1172/JCI117412

Tangirala, 1999, Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice, Circulation, 100, 1816, 10.1161/01.CIR.100.17.1816

Tardif, 2007, Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial, JAMA, 297, 1675, 10.1001/jama.297.15.jpc70004

Nissen, 2003, Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial, JAMA, 290, 2292, 10.1001/jama.290.17.2292

Waksman, 2010, A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome, J Am Coll Cardiol, 55, 2727, 10.1016/j.jacc.2009.12.067

Shaw, 2008, Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque, Circ Res, 103, 1084, 10.1161/CIRCRESAHA.108.182063

Tall, 2008, HDL, ABC transporters, and cholesterol efflux: implications for the treatment of atherosclerosis, Cell Metab, 7, 365, 10.1016/j.cmet.2008.03.001

Krieger, 2001, Scavenger receptor class B type I is a multiligand HDL receptor that influences diverse physiologic systems, J Clin Invest, 108, 793, 10.1172/JCI14011

Lim, 2013, Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL, Cell Metab, 17, 671, 10.1016/j.cmet.2013.04.002

Martel, 2013, Lymphatic vasculature mediates macrophage reverse cholesterol transport in mice, J Clin Invest, 123, 1571, 10.1172/JCI63685

Vrins, 2012, Trans-intestinal cholesterol efflux is not mediated through high density lipoprotein, J Lipid Res, 53, 2017, 10.1194/jlr.M022194

Vergeer, 2011, Genetic variant of the scavenger receptor BI in humans, N Engl J Med, 364, 136, 10.1056/NEJMoa0907687

Barter, 2004, Antiinflammatory properties of HDL, Circ Res, 95, 764, 10.1161/01.RES.0000146094.59640.13

Hine, 2012, Coincubation of PON1, APO A1, and LCAT increases the time HDL is able to prevent LDL oxidation, IUBMB Life, 64, 157, 10.1002/iub.588

Kontush, 2010, Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities, Curr Opin Lipidol, 21, 312, 10.1097/MOL.0b013e32833bcdc1

Cockerill, 1995, High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules, Arterioscler Thromb Vasc Biol, 15, 1987, 10.1161/01.ATV.15.11.1987

Westerterp, 2014, ATP-binding cassette transporters, atherosclerosis, and inflammation, Circ Res, 114, 157, 10.1161/CIRCRESAHA.114.300738

Tall, 2012, Cholesterol efflux: a novel regulator of myelopoiesis and atherogenesis, Arterioscler Thromb Vasc Biol, 32, 2547, 10.1161/ATVBAHA.112.300134

Westerterp, 2013, Deficiency of ATP-binding cassette transporters A1 and G1 in macrophages increases inflammation and accelerates atherosclerosis in mice, Circ Res, 112, 1456, 10.1161/CIRCRESAHA.113.301086

Zhu, 2008, Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages, J Biol Chem, 283, 22930, 10.1074/jbc.M801408200

Yvan-Charvet, 2008, Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions, Circulation, 118, 1837, 10.1161/CIRCULATIONAHA.108.793869

Whetzel, 2010, ABCG1 deficiency in mice promotes endothelial activation and monocyte-endothelial interactions, Arterioscler Thromb Vasc Biol, 30, 809, 10.1161/ATVBAHA.109.199166

De Nardo, 2014, High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3, Nat Immunol, 15, 152, 10.1038/ni.2784

Nofer, 2004, HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3, J Clin Invest, 113, 569, 10.1172/JCI200418004

Yuhanna, 2001, High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase, Nat Med, 7, 853, 10.1038/89986

Mineo, 2003, High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases, J Biol Chem, 278, 9142, 10.1074/jbc.M211394200

Terasaka, 2008, ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet, J Clin Invest, 118, 3701, 10.1172/JCI35470

Calabresi, 1997, Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins, Biochem Biophys Res Commun, 238, 61, 10.1006/bbrc.1997.7236

Blankenberg, 2003, Adhesion molecules and atherosclerosis, Atherosclerosis, 170, 191, 10.1016/S0021-9150(03)00097-2

Patel, 2011, The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease, J Am Coll Cardiol, 58, 2068, 10.1016/j.jacc.2011.08.030

Feig, 2011, HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells, Proc Natl Acad Sci USA, 108, 7166, 10.1073/pnas.1016086108

Julve, 2010, Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome, Arterioscler Thromb Vasc Biol, 30, 232, 10.1161/ATVBAHA.109.198226

Adams, 2013, Exercise training in patients with chronic heart failure promotes restoration of high-density lipoprotein functional properties, Circ Res, 113, 1345, 10.1161/CIRCRESAHA.113.301684

Besler, 2011, Mechanisms underlying adverse effects of HDL on eNOS-activating pathways in patients with coronary artery disease, J Clin Invest, 121, 2693, 10.1172/JCI42946

Holzer, 2012, Myeloperoxidase-derived chlorinating species induce protein carbamylation through decomposition of thiocyanate and urea: novel pathways generating dysfunctional high-density lipoprotein, Antioxid Redox Signal, 17, 1043, 10.1089/ars.2011.4403

Besler, 2012, Molecular mechanisms of vascular effects of high-density lipoprotein: alterations in cardiovascular disease, EMBO Mol Med, 4, 251, 10.1002/emmm.201200224

Marsche, 2004, 2-Chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis, Arterioscler Thromb Vasc Biol, 24, 2302, 10.1161/01.ATV.0000148703.43429.25

Mineo, 2012, Novel biological functions of high-density lipoprotein cholesterol, Circ Res, 111, 1079, 10.1161/CIRCRESAHA.111.258673

Luscher, 2014, High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target, Circ Res, 114, 171, 10.1161/CIRCRESAHA.114.300935

Suc, 1997, HDL and ApoA prevent cell death of endothelial cells induced by oxidized LDL, Arterioscler Thromb Vasc Biol, 17, 2158, 10.1161/01.ATV.17.10.2158

Riwanto, 2013, Altered activation of endothelial anti- and proapoptotic pathways by high-density lipoprotein from patients with coronary artery disease: role of high-density lipoprotein-proteome remodeling, Circulation, 127, 891, 10.1161/CIRCULATIONAHA.112.108753

Nofer, 2001, Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids, J Biol Chem, 276, 34480, 10.1074/jbc.M103782200

Feig, 2014, High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies, Circ Res, 114, 205, 10.1161/CIRCRESAHA.114.300760

Hewing, 2012, HDL and cardiovascular risk: time to call the plumber?, Circ Res, 111, 1117, 10.1161/CIRCRESAHA.112.280958

Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study, Lancet, 380, 572, 10.1016/S0140-6736(12)60312-2

Silbernagel, 2013, High-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality, Eur Heart J, 34, 3563, 10.1093/eurheartj/eht343

deGoma, 2008, Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches, J Am Coll Cardiol, 51, 2199, 10.1016/j.jacc.2008.03.016

Annema, 2013, High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis, Circ J, 77, 2432, 10.1253/circj.CJ-13-1025

Triolo, 2013, Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research, Biomark Med, 7, 457, 10.2217/bmm.13.35

Zhang, 2005, Hepatic expression of scavenger receptor class B type I (SR-BI) is a positive regulator of macrophage reverse cholesterol transport in vivo, J Clin Invest, 115, 2870, 10.1172/JCI25327

Khera, 2013, The addition of niacin to statin therapy improves high-density lipoprotein cholesterol levels but not metrics of functionality, J Am Coll Cardiol, 62, 1909, 10.1016/j.jacc.2013.07.025

Jafri, 2009, Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD, J Clin Lipidol, 3, 45, 10.1016/j.jacl.2008.12.003

Mackey, 2012, High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis), J Am Coll Cardiol, 60, 508, 10.1016/j.jacc.2012.03.060

DiDonato, 2013, Function and distribution of apolipoprotein A1 in the artery wall are markedly distinct from those in plasma, Circulation, 128, 1644, 10.1161/CIRCULATIONAHA.113.002624

Huang, 2014, An abundant dysfunctional apolipoprotein A1 in human atheroma, Nat Med, 20, 193, 10.1038/nm.3459

Holzer, 2011, Protein carbamylation renders high-density lipoprotein dysfunctional, Antioxid Redox Signal, 14, 2337, 10.1089/ars.2010.3640

Van Lenten, 1995, Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures, J Clin Invest, 96, 2758, 10.1172/JCI118345

Tolle, 2012, High-density lipoprotein loses its anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A, Cardiovasc Res, 94, 154, 10.1093/cvr/cvs089

Weichhart, 2012, Serum amyloid A in uremic HDL promotes inflammation, J Am Soc Nephrol, 23, 934, 10.1681/ASN.2011070668

Holzer, 2012, Psoriasis alters HDL composition and cholesterol efflux capacity, J Lipid Res, 53, 1618, 10.1194/jlr.M027367

Holzer, 2011, Uremia alters HDL composition and function, J Am Soc Nephrol, 22, 1331, 10.1681/ASN.2010111144

Tardif, 2014, Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial, Eur Heart J, 10.1093/eurheartj/ehu171

Levels, 2007, Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis, Biochim Biophys Acta, 1771, 1429, 10.1016/j.bbalip.2007.10.001

Drew, 2011, Reconstituted high-density lipoprotein infusion modulates fatty acid metabolism in patients with type 2 diabetes mellitus, J Lipid Res, 52, 572, 10.1194/jlr.P012518

Vaisar, 2007, Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL, J Clin Invest, 117, 746, 10.1172/JCI26206

Reilly, 2007, HDL proteomics: pot of gold or Pandora’s box?, J Clin Invest, 117, 595, 10.1172/JCI31608

Sreckovic, 2013, Distinct composition of human fetal HDL attenuates its anti-oxidative capacity, Biochim Biophys Acta, 1831, 737, 10.1016/j.bbalip.2012.12.015

Holzer, 2013, Aging affects high-density lipoprotein composition and function, Biochim Biophys Acta, 1831, 1442, 10.1016/j.bbalip.2013.06.004

Alwaili, 2011, The HDL proteome in acute coronary syndromes shifts to an inflammatory profile, Biochim Biophys Acta, 1821, 405, 10.1016/j.bbalip.2011.07.013

Mange, 2012, HDL proteome in hemodialysis patients: a quantitative nanoflow liquid chromatography–tandem mass spectrometry approach, PLoS One, 7, e34107, 10.1371/journal.pone.0034107

Watanabe, 2012, Proteomic profiling following immunoaffinity capture of HDL: association of acute phase proteins and complement factors with pro-inflammatory HDL in rheumatoid arthritis, Arthritis Rheum, 64, 1828, 10.1002/art.34363

Hoofnagle, 2012, Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures, Clin Chem, 58, 777, 10.1373/clinchem.2011.173856

Yassine, 2014, The application of multiple reaction monitoring and multi-analyte profiling to HDL proteins, Lipids Health Dis, 13, 8, 10.1186/1476-511X-13-8

Gordon, 2013, The effects of type 2 diabetes on lipoprotein composition and arterial stiffness in male youth, Diabetes, 62, 2958, 10.2337/db12-1753

Marsche, 2014, Anti-psoriatic treatment extends beyond the skin: recovering of high-density lipoprotein function, Exp Dermatol, 10.1111/exd.12483

Marhaug, 1982, Serum amyloid A protein in high density lipoprotein fraction of human acute phase serum, Lancet, 2, 1463, 10.1016/S0140-6736(82)91362-9

Sviridov, 2000, Identification of a sequence of apolipoprotein A-I associated with the activation of lecithin: cholesterol acyltransferase, J Biol Chem, 275, 19707, 10.1074/jbc.M000962200

Sorenson, 1999, Human serum paraoxonase/arylesterase’s retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: apolipoprotein A-I stabilizes activity, Arterioscler Thromb Vasc Biol, 19, 2214, 10.1161/01.ATV.19.9.2214

Castro, 1997, Biochemistry, 36, 2243, 10.1021/bi961191e

Zhong, 1994, Human ApoA-II inhibits the hydrolysis of HDL triglyceride and the decrease of HDL size induced by hypertriglyceridemia and cholesteryl ester transfer protein in transgenic mice, J Clin Invest, 94, 2457, 10.1172/JCI117614

Holzer, 2014, Anti-psoriatic therapy recovers high-density lipoprotein composition and function, J Invest Dermatol, 134, 635, 10.1038/jid.2013.359

Artl, 2000, Role of serum amyloid A during metabolism of acute-phase HDL by macrophages, Arterioscler Thromb Vasc Biol, 20, 763, 10.1161/01.ATV.20.3.763

Coetzee, 1986, Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition, J Biol Chem, 261, 9644, 10.1016/S0021-9258(18)67562-3

Malle, 1996, Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice, Eur J Clin Invest, 26, 427, 10.1046/j.1365-2362.1996.159291.x

Chiba, 2011, Serum amyloid A facilitates the binding of high-density lipoprotein from mice injected with lipopolysaccharide to vascular proteoglycans, Arterioscler Thromb Vasc Biol, 31, 1326, 10.1161/ATVBAHA.111.226159

Badolato, 1994, Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes, J Exp Med, 180, 203, 10.1084/jem.180.1.203

de Beer, 1996, Structure of the mouse Saa4 gene and its linkage to the serum amyloid A gene family, Genomics, 34, 139, 10.1006/geno.1996.0253

Strunk, 1983, Human peripheral blood monocyte-derived macrophages produce haemolytically active C3 in vitro, Immunology, 49, 169

Oksjoki, 2003, Role of complement activation in atherosclerosis, Curr Opin Lipidol, 14, 477, 10.1097/00041433-200310000-00008

Watanabe, 2009, Hemoglobin and its scavenger protein haptoglobin associate with apoA-1-containing particles and influence the inflammatory properties and function of high density lipoprotein, J Biol Chem, 284, 18292, 10.1074/jbc.M109.017202

Green, 1980, Human apolipoprotein A-IV. Intestinal origin and distribution in plasma, J Clin Invest, 65, 911, 10.1172/JCI109745

Goldberg, 1990, Lipoprotein ApoC-II activation of lipoprotein lipase. Modulation by apolipoprotein A-IV, J Biol Chem, 265, 4266, 10.1016/S0021-9258(19)39557-2

Steinmetz, 1985, Activation of lecithin: cholesterol acyltransferase by human apolipoprotein A-IV, J Biol Chem, 260, 2258, 10.1016/S0021-9258(18)89547-3

Inadera, 1993, A missense mutation (Trp -->26Arg) in exon 3 of the apolipoprotein CII gene in a patient with apolipoprotein CII deficiency (apo CII-Wakayama), Biochem Biophys Res Commun, 193, 1174, 10.1006/bbrc.1993.1749

Jong, 1999, Role of ApoCs in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3, Arterioscler Thromb Vasc Biol, 19, 472, 10.1161/01.ATV.19.3.472

Kawakami, 2008, Toll-like receptor 2 mediates apolipoprotein CIII-induced monocyte activation, Circ Res, 103, 1402, 10.1161/CIRCRESAHA.108.178426

Kawakami, 2008, Apolipoprotein CIII links hyperlipidemia with vascular endothelial cell dysfunction, Circulation, 118, 731, 10.1161/CIRCULATIONAHA.108.784785

Jensen, 2012, Apolipoprotein C-III as a potential modulator of the association between HDL-cholesterol and incident coronary heart disease, J Am Heart Assoc, 1, 10.1161/JAHA.111.000232

Ooi, 2011, Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease, J Lipid Res, 52, 794, 10.1194/jlr.M011163

Sevvana, 2009, Serendipitous fatty acid binding reveals the structural determinants for ligand recognition in apolipoprotein M, J Mol Biol, 393, 920, 10.1016/j.jmb.2009.08.071

Karuna, 2011, Plasma levels of sphingosine-1-phosphate and apolipoprotein M in patients with monogenic disorders of HDL metabolism, Atherosclerosis, 219, 855, 10.1016/j.atherosclerosis.2011.08.049

Nofer, 2012, Hyperlipidaemia and cardiovascular disease: HDL, inflammation and surprising results of AIM-HIGH study, Curr Opin Lipidol, 23, 260, 10.1097/MOL.0b013e328353c4e6

Wolfrum, 2005, Apolipoprotein M is required for prebeta-HDL formation and cholesterol efflux to HDL and protects against atherosclerosis, Nat Med, 11, 418, 10.1038/nm1211

Christoffersen, 2008, Effect of apolipoprotein M on high density lipoprotein metabolism and atherosclerosis in low density lipoprotein receptor knock-out mice, J Biol Chem, 283, 1839, 10.1074/jbc.M704576200

Jones, 2002, Clusterin, Int J Biochem Cell Biol, 34, 427, 10.1016/S1357-2725(01)00155-8

Hoofnagle, 2010, Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia, Arterioscler Thromb Vasc Biol, 30, 2528, 10.1161/ATVBAHA.110.212894

Moradi, 2009, Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease, Transl Res, 153, 77, 10.1016/j.trsl.2008.11.007

Vaziri, 2009, In vitro stimulation of HDL anti-inflammatory activity and inhibition of LDL pro-inflammatory activity in the plasma of patients with end-stage renal disease by an apoA-1 mimetic peptide, Kidney Int, 76, 437, 10.1038/ki.2009.177

Vaziri, 2011, Salutary effects of hemodialysis on low-density lipoprotein proinflammatory and high-density lipoprotein anti-inflammatory properties in patient with end-stage renal disease, J Natl Med Assoc, 103, 524, 10.1016/S0027-9684(15)30368-0

Mackness, 2012, The antioxidant properties of high-density lipoproteins in atherosclerosis, Panminerva Med, 54, 83

Aviram, 2010, Atherosclerosis: cell biology and lipoproteins—oxidative stress and paraoxonases regulate atherogenesis, Curr Opin Lipidol, 21, 163, 10.1097/MOL.0b013e3283376936

Bhattacharyya, 2008, Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk, JAMA, 299, 1265, 10.1001/jama.299.11.1265

Rosenson, 2012, Cholesterol efflux and atheroprotection: advancing the concept of reverse cholesterol transport, Circulation, 125, 1905, 10.1161/CIRCULATIONAHA.111.066589

Rosenson, 2012, Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2, J Lipid Res, 53, 1767, 10.1194/jlr.R024190

Cheung, 1984, Characterization of lipoprotein particles isolated by immunoaffinity chromatography. Particles containing A-I and A-II and particles containing A-I but no A-II, J Biol Chem, 259, 12201, 10.1016/S0021-9258(20)71339-6

Rosenson, 2011, HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events, Clin Chem, 57, 392, 10.1373/clinchem.2010.155333

Camont, 2013, Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities, Arterioscler Thromb Vasc Biol, 33, 2715, 10.1161/ATVBAHA.113.301468

Stahlman, 2013, Dyslipidemia, but not hyperglycemia and insulin resistance, is associated with marked alterations in the HDL lipidome in type 2 diabetic subjects in the DIWA cohort: impact on small HDL particles, Biochim Biophys Acta, 1831, 1609, 10.1016/j.bbalip.2013.07.009

Deakin, 2007, HDL oxidation compromises its influence on paraoxonase-1 secretion and its capacity to modulate enzyme activity, Arterioscler Thromb Vasc Biol, 27, 1146, 10.1161/ATVBAHA.107.141747

Marsche, 2002, Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport, J Biol Chem, 277, 32172, 10.1074/jbc.M200503200

Marsche, 2008, Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro, Cardiovasc Res, 79, 187, 10.1093/cvr/cvn051

Bergt, 2004, The myeloperoxidase product hypochlorous acid oxidizes HDL in the human artery wall and impairs ABCA1-dependent cholesterol transport, Proc Natl Acad Sci USA, 101, 13032, 10.1073/pnas.0405292101